WASHINGTON DC, July 29 /PRNewswire/ -- Athera Biotechnology announced the Award from NACB (National Academy of Clinical Biochemistry) for Distinguished Abstracts at the annual AACC (American Association of Clinical Chemistry) meeting in Washinton DC was awarded to Athera Biotechnology founder Johan Frostegard and his colleagues. The abstract was one of 26 selected for the award, among over 700 accepted abstracts. Winners will be honored at NACB Award luncheon held at the AACC meeting on July 30.
Frostegard's abstract describes a study where low levels of antibodies against phosphorylcholine (anti-PC) were measured using an enzyme linked immunoassay (ELISA) by CVDefine(TM), a new kit developed by Athera. The findings indicate that low levels of IgM anti-PC are associated with an increased risk of cardiovascular disease (CVD) in a population. Frostegard and colleagues conclude that low levels of anti-PC could be a novel risk marker for CVD and ischemic stroke, especially in men.
Athera Biotechnologies AB develops novel products for risk assessment and treatment of CVD. The company was founded in 2002 to exploit findings made by Professors Johan Frostegard and Ulf de Faire on the critical role of phospholipid antibodies (aPL) in the inflammatory process of cardiovascular disease. Athera is based in Karolinska Institutet Science Park in Stockholm and main investors include Karolinska Development and Baltic Sea Foundation. Athera is also a major partner in the highly ranked EU-project CVDIMMUNE lead by Karolinska Institutet. The project involves 10 academic and industrial partners, including Phadia GmbH, Johannes Gutenberg-University Mainz and Leiden University Medical Center.
|SOURCE Athera Biotechnologies AB|
Copyright©2008 PR Newswire.
All rights reserved